Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    s.l. : American Chemical Society
    Journal of the American Chemical Society 94 (1972), S. 4348-4350 
    ISSN: 1520-5126
    Source: ACS Legacy Archives
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0584
    Keywords: High grade Non Hodgkin's lymphoma ; Upfront therapy ; Salvage therapy ; MACOP-B
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0584
    Keywords: Key words Acute myeloid leukemia ; Myelodysplastic syndrome ; Secondary leukemia ; Interleukin-2 ; G-CSF
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18–76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged ≤60 years and 35% aged 〉60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2. Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation. The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19%. Overall survival of all patients was 8 months, and 21 months for the CR patients. Median survival was significantly longer among patients aged ≤60 years than among the older patients (16 vs 6 months, p〈0.001). Median duration of survival and relapse-free survival were not statistically different in the two IL-2 treatment arms.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1439-0973
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung In einer offenen, randomisierten Vergleichsstudie wurde die initiale empirische Monotherapie mit Meropenem in einer Dosierung von 3 × 1g täglich verglichen mit Imipenem/Cilastatin in der gleichen Dosierung bei 66 Fieberepisoden von 61 erwachsenen neutropenischen Patienten. 72 Stunden nach Therapiebeginn erhielten noch 25/31 Patienten aus der Meropenem-Gruppe und 24/30 Patienten aus der Behandlungsgruppe mit Imipenem/Cilastatin die usprünglich zugewiesene Initialtherapie (Hauptzielkriterium). Bei Therapieende waren in der Meropenem-Gruppe 18/31 Episoden geheilt oder gebessert gegenüber 18/30 in der Gruppe mit Imipenem/Cilastatin. Weitere 10 Infektionsepisoden, die initial mit Meropenem behandelt wurden, und sechs Infektionsepisoden aus der Vergleichsgruppe konnten erfolgreich behandelt werden, nachdem eine zusätzliche antimikrobielle Substanz verabreicht worden war (Heilung nach Therapiemodifikation). Das zufriedenstellende bakteriologische Ansprechen (Keimelimination sowie vermutete Keimelimination) mit der Initialtherapie Meropenem betrug 9/11 und 14/16 mit Imipenem/Cilastatin. Beide Antibiotika wurden gut vertragen; es wurden jedoch unter Imipenem/Cilastatin mehr Fälle von Übelkeit und/oder Erbrechen registriert (7/33 vs 2/33 unter Meropenem). Die Carbapenem-Antibiotika Meropenem und Imipenem/Cilastatin scheinen geeignet für die empirische Monotherapie bei Fieberepisoden neutropenischer Patienten zu sein. Meropenem erlaubt durch seine offensichtlich bessere Verträglichkeit im Vergleich zu Impienem/Cilastatin auch eine optimale Dosierung bei diesem Patientengut.
    Notes: Summary In a nonblind, randomised, parallel-group study, initial empirical monotherapy with meropenem 1 g intravenously every 8 h was compared to an identical dosage of imipenem/cilastatin for the treatment of 66 febrile episodes in 61 adult neutropenic patients. 25/31 episodes treated with meropenem and 24/30 imipenem/cilastatin-treated episodes were still receiving unmodified therapy at 72 h (primary endpoint); this difference was not statistically significant. By the end of the treatment courses, 18/31 meropenem-treated episodes had responded clinically (cured or improved) compared with 18/30 episodes treated with imipenem/cilastatin. Another ten episodes initially treated with meropenem and six episodes treated with imipenem/cilastatin were cured after an additional antimicrobial agent had been administered (cured with modification). Satisfactory bacteriological responses (eradication plus presumed eradication) at the end of unmodified therapy was 9/11 in the meropenem group and 14/16 in the comparator group. Both regimes were well tolerated; however, there were more reports of nausea and/or vomiting in the imipenem/cilastatin group (7/33 vs. 2/33 in the meropenem group). The carbapenems meropenem and imipenem/cilastatin appear to be suitable agents for empirical monotherapy of febrile episodes in neutropenic patients. Meropenem may be better tolerated than imipenem/cilastatin, allowing optimal dosing in this patient population.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...